Intranasal Drug Delivery Market

Intranasal Drug Delivery Market is segmented By Type (Spray, Drops, Gel, Powder), By Container Type (Pressurized Container, Non-pressurized Container), By Application (Nasal Congestion, Sinusitis, Asthma, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

[150 Pages Report] Intranasal Drug Delivery Market is expected to grow at a high CAGR 11.5% during the forecasting period (2023-2030). Intranasal drug delivery means the administration of the drug through the nasal route. Intranasal drugs are generally prescribed for the treatment of local infection in the nasal cavity, acute or chronic treatments, anxiety, or depression. Respiratory-related disorders such as asthma and sinusitis are the most common nose and lungs-related diseases and can be treated more efficiently with intranasal drug delivery. According to the Centre for Disease Control and Prevention (CDC), around 30 million people had sinusitis in 2018. Furthermore, as per the World Health Organization (WHO), worldwide, 1 out of 12 individuals have asthma, and the number is increasing every year.  Local anesthetics, antibiotics, pain relief drugs, calcium supplements, and antihistamines are delivered through nasal cavity as it leads to increased efficiency of the drug. The intranasal route of administration of drugs provides direct access to the systemic circulation and offers several other advantages, such as faster absorption of drugs, faster spreading of the drug in the blood, and potential of direct drug delivery to the brain through olfactory nerves. Intranasal drug delivery is a minimally invasive form of administration of drugs and offers a needleless and systematic solution to drug delivery. According to Binghamton University, State University at New York, Narcan (naloxone), nasal spray, was considered as the easiest product to deliver in August 2018 as drug delivery via nasal route lacks lagging as in the case of the oral route of administration.

Intranasal Drug Delivery Market - Strategic Insights

To Get a Free Sample Click here

Market Dynamics

The market is driven by the growing awareness among the common population, technological innovations in the field, increase in R&D, and high prevalence of cardiovascular diseases, cancer, and diabetes. Growing incidence of chronic diseases is one of the major contributors to the growth of the intranasal drug delivery market. According to CDC, 6 in 10 adults in the U.S. are suffering from at least one chronic disease, and four in 10 adults are suffering from two or more chronic diseases. Lack of skilled medical professionals, risk of side effects associated and market recalls, are going to restrain the market in the forecast period.

Market Segmentation

Intranasal drug delivery market is segmented by type as Spray, Drops, Gel and Powder, container type as Pressurized Container and Non-pressurized Container and by application as Nasal Congestion, Sinusitis, Asthma, and Others.

Nasal Sprays are used for cold relief and allergies. Nasal Sprays are expected to hold the largest market share in the period of forecast. According to the American Academy of Allergy, Asthma, and Immunology (AAAAI), worldwide, allergic rhinitis affects between 10% and 30 % of the population. Furthermore, Roughly 13% of people 18 and over in the U.S. have sinusitis. Nasal sprays are of different types such as Decongestant sprays shrink swollen blood vessels and tissues in your nose that cause congestion, Antihistamine sprays relieve congestion, itchy and runny nose, and sneezing and Steroid Nasal Sprays reduce congestion, sneezing, and itchy, watery eyes.

Nasal drops are used for temporary relief of nasal congestion caused by various conditions including common cold, sinusitis, hay fever, and allergies. It works by narrowing the blood vessels in the nose area, reducing swelling and congestion. Nasal Drops segment is expected to grow at the highest CAGR over the period of forecast. 

Geographical Analysis

Geographically, the global intranasal drug delivery market is divided into North America, Europe, South America, Asia-Pacific, and the Middle East and Africa.

North America is expected to hold the largest market share over the period of forecast due to increase in awareness about nasal mode for delivering drugs and improved healthcare facilities and infrastructure. Government initiatives and favorable reimbursement policies are growing to help the growth of the market in North America. Asia is expected to increase at a high growth rate in the forecast period. China and India are expected to dominate the intranasal drug delivery markets in Asia due to large investments by various major companies, rising population, and government funding. According to the CDC, in 2017, 1 in 13 people had asthma. Around 26 million Americans had asthma, that is 8.3% of adults. Furthermore, Asthma is a leading chronic disease in children.

Europe is expected to be the second-largest market over the period of forecast due to investment by major companies, rise in chronic disease and allergies, and a well aware population. According to Allergy UK, allergy is the most common chronic disease in Europe. Approximately 20% of patients with allergies are associated with a risk of possible asthma attack, anaphylactic shock, or even death from an allergic reaction.

Competitive Analysis

• Some of the major key players in the market are AstraZeneca, Baxter International, Inc., Becton, Dickinson and Company, GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG, Pfizer Inc., Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., Aegis Therapeutics LLC., Teleflex Medical Europe Ltd and Procter & Gamble. Few of the recent developments on the key companies in the market include – 

• In February 2019, Optinose announced that the United States Patent and Trademark Office (USPTO) issued four patents to the company covering XHANCE® (fluticasone propionate) nasal spray.

• In January 2019, FDA approved sumatriptan nasal spray (Tosymra) by Promius Pharma for treatment of acute migraine with or without aura in adults.

• In July 2018, Eli Lilly and Company announced that their therapeutic spray (intranasal glucagon) for the treatment of low blood sugar is expected to be approved by 2019 in the U.S. and Europe regions.

• In April 2018, Allergan announced the launch of the TrueTear® Intranasal Neurostimulation Device during 2018 ASCRS-ASOA annual meeting.

• In April 2018, Dr. Reddy’s Laboratories, along with its subsidiary Promius Pharma, LLC, announced the filing of their New Drug Application (NDA) for DFN-02, for the treatment of migraine.

Trending Topics

United States Heartworm Treatment Market

Silver & Collagen Wound Care Market

Digital Therapeutics Market